Automated Pipeline Can ID Clinically Significant Mitral Regurgitation
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- An automated pipeline can identify clinically significant mitral regurgitation (MR) among patients undergoing transthoracic echocardiograms, according to a study published online Aug. 12 in Circulation.
Amey Vrudhula, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues used 58,614 transthoracic echocardiograms (2,587,538 videos) to develop a fully automated deep learning pipeline for identifying apical four-chamber view videos with color Doppler echocardiography and detecting clinically significant MR. The model was tested internally on 1,800 studies from Cedars-Sinai Medical Center and externally in a geographically distinct cohort of 915 studies (80,833 and 46,890 videos, respectively).
The researchers found that the view classifier demonstrated an area under the curve (AUC) of 0.998 in the held-out Cedars-Sinai Medical Center test set and correctly identified 3,452 of 3,539 echocardiography videos as having color Doppler information across the mitral valve (sensitivity and specificity of 0.975 and 0.999, respectively, compared with manually curated videos). The view classifier correctly identified 1,051 of 1,055 manually curated videos with color Doppler information across the mitral valve in the external test cohort (sensitivity and specificity, 0.996 and 0.999, respectively). In the internal test cohort, the AUC was 0.916 and 0.934 for detecting MR moderate or greater in severity and severe MR, respectively; in the external test cohort, the corresponding AUCs were 0.951 and 0.969.
"Mitral regurgitation is a common but often missed valvular heart disease. It can be challenging to precisely assess the disease severity, which is critical to know which patients can take a watch-and-wait approach and which should proceed to an intervention," coauthor David Ouyang, M.D., from the Smidt Heart Institute in Los Angeles, said in a statement.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Time From Drug Approval to Reimbursement Longer in U.S. Than Some European Countries
TUESDAY, Sept. 3, 2024 -- Time from approval to reimbursement of new drugs varies between countries and is shortest in Switzerland and Germany, both of which include health...
Inflammation, Cholesterol, Lipoprotein(a) Predict 30-Year Cardiovascular Outcomes in Women
TUESDAY, Sept. 3, 2024 -- A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels predict the...
Annual Mammography Screening Tied to Better Outcomes
TUESDAY, Sept. 3, 2024 -- Annual mammography screening for breast cancer is associated with a lower risk for a late-stage diagnosis and better overall survival across clinical and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.